Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
Experience the interactive Multimedia News Release here.
During the call, Dr. Stewart Tepper, Professor of Neurology at the Geisel School of Medicine at Dartmouth and Vice President of the New England Institute for Neurology and Headache, will discuss the current migraine treatment landscape and provide his clinical perspective on SYMBRAVO. The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the live webcast, please click here.
Conference Call Information
To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast can be accessed on the 'Webcasts & Presentations' page of the 'Investors' section of the Company's website at axsome.com. A replay of the webcast will be available for approximately 30 days following the live event.
About Migraine
Migraine is a serious neurological condition characterized by recurrent attacks of pulsating, often severe and disabling head pain associated with nausea, sensitivity to light, and sensitivity to sound.2 It is estimated that over 39 million Americans suffer from migraine, and it is the leading cause of disability among neurological disorders in the United States according to the American Migraine Foundation.3-5 Extensive surveys of migraine sufferers underscore the unmet need for therapies that work faster, more consistently, and result in less symptom recurrence.6,7 Over 70% of patients report experiencing an inadequate response to their oral, acute migraine treatment.8
About SYMBRAVO
SYMBRAVO is a novel, oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults. SYMBRAVO consists of MoSEIC™ meloxicam and rizatriptan. Meloxicam is a new molecular entity for migraine enabled by Axsome's MoSEIC (Molecular Solubility Enhanced Inclusion Complex) technology, which enables the rapid absorption of meloxicam while maintaining a long plasma half-life. Meloxicam is a COX-2 preferential non-steroidal anti-inflammatory drug (NSAID) and rizatriptan is a 5-HT1B/1D agonist. SYMBRAVO is designed to provide rapid, enhanced, and consistent migraine pain relief, and reduced symptom recurrence. The exact mechanism of action of SYMBRAVO in the treatment of acute migraine is unknown.
For more information, visit www.symbravo.com.
What is SYMBRAVO (sim-BRAH-voh)? SYMBRAVO is a combination of meloxicam (an NSAID) and rizatriptan (a triptan). SYMBRAVO is an oral prescription medicine used to treat acute migraine headaches with or without aura in adults.
SYMBRAVO is not used to prevent or decrease the number of migraine headaches you have or for treatment of hemiplegic or basilar migraines. SYMBRAVO is not indicated as a treatment for cluster headaches or for use in children.
WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT SYMBRAVO?
SYMBRAVO may increase the risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase with increasing doses, and longer use, of NSAIDs.
Do not take SYMBRAVO right before or after a heart surgery called a 'coronary artery bypass graft' (CABG).
Avoid taking SYMBRAVO after a recent heart attack unless your healthcare provider (HCP) tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack.
Stop taking SYMBRAVO and get emergency help right away if you have any of the following symptoms which can be indicative of a heart attack or stroke:
discomfort in your chest that lasts for more than a few minutes, or that goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw, or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
weakness in one part or one side of your body
slurred speech
People with risk factors for heart disease should not take SYMBRAVO unless a heart exam is done and shows no problem. You have higher risk for heart disease if you:
have high blood pressure
have high cholesterol
smoke
are overweight
have diabetes or a family history of diabetes
SYMBRAVO can increase the risk of potentially life-threatening bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach, and intestines that can occur anytime during use and without warning symptoms.
SYMBRAVO may cause serious allergic or skin reactions which can be life-threatening. Stop taking SYMBRAVO and get emergency help right away if you develop:
sudden wheezing or problems breathing or swallowing
rash or reddening of your skin with blisters or peeling
blisters or bleeding of your lips, eye lids, mouth, nose, or genitals
swelling of your lips, tongue, throat or body
fainting
SYMBRAVO already contains an NSAID (meloxicam). Do not use SYMBRAVO with other medicines to lessen pain or fever or with other medicines for colds or sleeping problems without talking to your HCP first, because they may contain an NSAID also.
Do not take SYMBRAVO if you:
have or had heart problems or right before or after heart bypass surgery
have or had a stroke or transient ischemic attack (TIA)
have or had blood vessel problems of your legs and arms, stomach (ischemic bowel disease), or kidneys
have or had hemiplegic or basilar migraines
have uncontrolled high blood pressure
take propranolol containing medicines
have taken other triptan or ergot-containing medicines within the last 24 hours
take an antidepressant medicine called monoamine oxidase inhibitor (MAOI) or have taken a MAOI within the last 2 weeks
are allergic to meloxicam, rizatriptan, NSAIDs, or any of the ingredients in SYMBRAVO
have had an asthma attack, hives, or other allergic reaction after taking aspirin or any other NSAIDs
have moderate to severe kidney problems and are at risk of kidney failure or if you are on dialysis
SYMBRAVO may cause serious side effects. These serious side effects include:
heartbeats that are too fast or too slow (arrhythmias)
new or worse high blood pressure
heart failure
life-threatening skin reactions
liver or kidney problems including organ failure
low red blood cell count (anemia)
asthma attacks in people who have asthma
Medication Overuse Headaches: Some people who use too many SYMBRAVO tablets may have worse headaches. If your headaches get worse, your HCP may decide to stop your treatment with SYMBRAVO.
Stop taking SYMBRAVO and get emergency help right away if you have any of the following:
Stomach and intestinal problems. Symptoms of gastrointestinal and colonic ischemic events may include sudden or severe stomach pains even after meals; sudden weight loss; severe nausea, vomiting, constipation, diarrhea; and bloody diarrhea.
Circulation problems to legs and feet. Symptoms of peripheral vascular ischemia may include cramping and pain in your legs and hips; heaviness or tightness in leg muscles; burning, aching, numbness, tingling, or weakness in your legs, feet, or toes; cold feelings or color changes in one or both legs or feet.
Serotonin syndrome. Can happen when taking SYMBRAVO with antidepressant medicines called SSRIs or SNRIs. Stop taking SYMBRAVO and call your doctor right away if you have any of the following symptoms:
mental status changes including agitation, hallucinations, or coma
fast heartbeat
changes in your blood pressure
increased body temperature
tight muscles
trouble walking
Stop taking SYMBRAVO and call your healthcare provider right away if you have any of the following symptoms:
nausea
vomiting blood
more tired or weaker than usual
blood in your bowel movement or it is black and sticky like tar
diarrhea
itching, skin rash, or blisters with fever
unusual weight gain
your skin or eyes look yellow
indigestion or stomach pain
swelling of the arms, legs, hands, or feet
flu-like symptoms
tenderness in your right upper side
vision problems
COMMON SIDE EFFECTS
The most common side effects of SYMBRAVO include dizziness and tiredness.
These are not all the possible side effects of SYMBRAVO. Tell your doctor if you have any side effects. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1–800-FDA-1088.
BEFORE USING
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
It is important to tell your HCP if you are taking:
Propranolol containing medicines such as Inderal® LA or Innopran® XL
Aspirin or other anti-coagulants (blood thinners)
Medicines to help your mood including SSRIs and SNRIs
If you are unsure if you take any of these medicines, ask your HCP. They can tell you if it is safe to take SYMBRAVO with your other medicines.
Tell your HCP if you are pregnant or plan to become pregnant. SYMBRAVO is not recommended during pregnancy. Taking NSAIDs, including SYMBRAVO, at about 20 weeks of pregnancy or later may harm your unborn baby. NSAIDs, including SYMBRAVO, should not be taken after about 30 weeks of pregnancy.
Tell your HCP if you are breastfeeding or plan to breastfeed.
Tell your HCP about all your medical conditions, including if you:
have or have had heart problems, high blood pressure, chest pain, or shortness of breath
have any risk factors for heart or blood vessel problems
have kidney or liver problems
have asthma
Review the list below with your HCP. SYMBRAVO may not be right for you if:
take daily preventative aspirin
you are pregnant or plan to become pregnant
you are breastfeeding or plan to breastfeed
HOW TO TAKE
SYMBRAVO is available by prescription only.
Take SYMBRAVO exactly as instructed by your HCP.
The maximum daily dose of SYMBRAVO is 1 tablet. Talk to your HCP about what to do if your headache does not go away or comes back.
Take SYMBRAVO for the shortest time needed.
Swallow SYMBRAVO tablets whole. Do not crush, chew, or divide the tablets.
SYMBRAVO can be taken with or without food.
Do not give SYMBRAVO to other people.
If you take too much SYMBRAVO call your poison control center at 1-800-222-1222 or go to the nearest hospital emergency room right away.
LEARN MORE
For more information about SYMBRAVO, call 866-496-2976 or visit SYMBRAVO.com.
This summary provides basic information about SYMBRAVO but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other HCP about SYMBRAVO and how to take it. Your HCP is the best person to help you decide if SYMBRAVO is right for you.
SYM CON BS 01/2025
Please see full Prescribing Information, including Boxed Warning for risk of serious cardiovascular and gastrointestinal adverse events, and Medication Guide.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder and excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain's biggest problems so patients and their loved ones can flourish. For more information, please visit the Company's website at www.axsome.com.
Forward Looking Statements
Certain matters discussed in this press release are 'forward-looking statements'. The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company's Sunosi®, Auvelity®, and Symbravo® products and the success of the Company's efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company's ability to maintain and expand payer coverage; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund the Company's disclosed clinical trials, which assumes no material changes to the Company's currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company's ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application ('NDA') for any of the Company's current product candidates; the Company's ability to fund additional clinical trials to continue the advancement of the Company's product candidates; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration ('FDA') or other regulatory authority approval of, or other action with respect to, the Company's product candidates, including statements regarding the timing of any NDA submission; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products and product candidates, if approved; the Company's anticipated capital requirements, including the amount of capital required for the commercialization of Sunosi, Auvelity, and Symbravo and for the Company's commercial launch of its other product candidates, if approved, and the potential impact on the Company's anticipated cash runway; the Company's ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.
Investors:Mark JacobsonChief Operating Officer(212) 332-3243mjacobson@axsome.com
Media:Darren OplandDirector, Corporate Communications(929) 837-1065dopland@axsome.com
References
SYMBRAVO Prescribing Information. SYMBRAVO U.S. Product Information. January 2025. New York, NY. Axsome Therapeutics, Inc.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211.
Ashina M, Katsarava Z et al. Migraine: epidemiology and systems of care. Lancet. 2021 Apr 17;397(10283):1485-1495.
American Migraine Foundation. 2023.
Steiner TJ, et al. Migraine remains the second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137.
Smelt AF, Louter MA et al. What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment? Results of a Delphi study. PLoS One. 2014 Jun 16;9(6):e98933. doi: 10.1371/journal.pone.0098933
Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39(suppl 2):S20-S26.
Lipton RB, Munjal S et al. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. Headache. 2019 Sep;59(8):1310-1323. doi: 10.1111/head.13588
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
20 minutes ago
- Boston Globe
US and Mexico sign deal to stop sewage release into Tijuana River
Lee Zeldin, the administrator of the Environmental Protection Agency, who traveled to Mexico to sign the memorandum of understanding with Alicia Bárcena Ibarra, Mexico's environment secretary, wrote in a statement that the countries are aiming for a 'permanent, 100% solution.' Under the deal, Mexico agreed to complete an allocation of $93 million toward sanitation infrastructure, and complete all projects by Dec. 31, 2027, the EPA said. The United States, which had withheld funds for water infrastructure improvements on the border, will release money to complete the rehabilitation of a pump station and other projects. Advertisement 'The Trump administration is proud to deliver this massive environmental and national security win for Americans in the San Diego area who have been living with this disgusting raw sewage flowing into their communities for far too long,' Zeldin said in a statement. Advertisement Bárcena Ibarra said in a statement the agreement 'strengthens collaboration to address environmental and health challenges along the northern border.' San Diego County residents have suffered acutely. The Office of the Naval Inspector General this year found that more than 1,100 Navy recruits contracted gastrointestinal illnesses after training in southern San Diego waters. And nearly half of the 40,900 households in the region have experienced health problems, including rashes and shortness of breath, that were most likely attributable to the sewage, according to the US Centers for Disease Control and Prevention. The agreement comes three months after Zeldin visited San Diego to begin negotiations with Mexico. It drew praise from local officials, including from Democrats, but some environmental advocates said more needs to be done. Jim Desmond, a Republican supervisor of the San Diego County Board of Supervisors, wrote on the social platform X that the announcement 'marks a significant step forward.' He said the federal government had previously failed to hold Mexico accountable for the sewage flowing into California. 'Our beaches must be clean, safe, and open year-round — anything less is unacceptable,' he wrote. Todd Gloria, the mayor of San Diego and a Democrat, thanked Zeldin on X and called the deal 'a huge step toward ending this crisis.' Matthew Tejada, senior vice president of environmental health for the Natural Resources Defense Council, an environmental group, called the agreement a good start. 'It's great that we're starting to roll up our sleeves' on this issue, he said. But he added that the waste-water improvements are enormous and complicated infrastructure projects that are likely going to be hit with unexpected problems, including worsening levels of runoff and sewage exacerbated by climate-fueled storms. 'These are really tough projects to implement, with really elusive outcomes,' he said. Advertisement This article originally appeared in
Los Angeles Times
an hour ago
- Los Angeles Times
Criminalization or support? President Trump's executive order on homelessness gets mixed reaction
An executive order signed by President Trump purporting to protect Americans from 'endemic vagrancy, disorderly behavior, sudden confrontations, and violent attacks' attributed to homelessness has left local officials and homeless advocates outraged over its harsh tone while also grasping for a hopeful message in its fine print. The order Trump signed Thursday would require federal agencies to reverse precedents or consent decrees that impede U.S. policy 'encouraging civil commitment of individuals with mental illness who pose risks to themselves or the public or are living on the streets and cannot care for themselves.' It ordered those agencies to 'ensure the availability of funds to support encampment removal efforts.' Depending on how that edict is carried out, it could extend a lifeline for Mayor Karen Bass' Inside Safe program, which has eliminated dozens of the city's most notable encampments but faces budget challenges to maintain the hotel and motel beds that allow people to move indoors. Responding to the order Friday, Bass said she was troubled that it called for ending street homelessness and moving people into rehabilitation facilities at the same time as the administration's cuts to Medicaid have affected funding 'streams for facilities for people to stay in, especially people who are disabled.' 'Of course I'm concerned about any punitive measures,' Bass said. 'But first and foremost, if you want to end street homelessness, then you have got to have housing and services for people who are on the street.' Kevin Murray, president and chief executive of the Weingart Center homeless services and housing agency, saw ambiguity in the language. 'I couldn't tell whether he is offering money for people who want to do it his way or taking money away from people who don't do it his way,' Murray said. Others took their cue from the order's provocative tone set in a preamble declaring that the overwhelming majority of the 274,224 people reported living on the street in 2024 'are addicted to drugs, have a mental health condition, or both.' The order contradicted a growing body of research finding that substance use and mental illness, while significant, are not overriding factors in homelessness. 'Nearly two-thirds of homeless individuals report having regularly used hard drugs like methamphetamines, cocaine, or opioids in their lifetimes. An equally large share of homeless individuals reported suffering from mental health conditions.' A February study by the Benioff Homeless and Housing Initiative at UC San Francisco found that only about 37% of more than 3,000 homeless people surveyed in California were using illicit drugs regularly, but just over 65% reported having regularly used at some point in their lives. More than a third said their drug use had decreased after they became homeless and one in five interviewed in depth said they were seeking treatment but couldn't get it. 'As with most executive orders, it doesn't have much effect on its own,' said Steve Berg, chief policy officer for the National Alliance to End Homelessness. 'It tells the federal agencies to do different things. Depending on how the federal agencies do those things, that's what will have the impact.' In concrete terms, the order seeks to divert funding from two pillars of mainstream homelessness practice, 'housing first,' the prioritization of permanent housing over temporary shelter, and 'harm reduction,' the rejection of abstinence as a condition of receiving services and housing. According to the order, grants issued under the Substance Abuse and Mental Health Services Administration should 'not fund programs that fail to achieve adequate outcomes, including so-called 'harm reduction' or 'safe consumption' efforts that only facilitate illegal drug use and its attendant harm.' And the Secretary of Health and Human Services and the Secretary of Housing and Urban Development should, to the extent permitted by law, end support for 'housing first' policies that 'deprioritize accountability and fail to promote treatment, recovery, and self-sufficiency.' To some extent, those themes reflect shifts that have been underway in the state and local response to homelessness. Under pressure from Gov. Gavin Newsom, the California legislature established rules allowing relatives and service providers to refer people to court for treatment and expanded the definition of gravely disabled to include substance use. Locally, Bass' Inside Safe program and the county's counterpart, Pathway Home, have prioritized expanding interim housing to get people off the streets immediately. Trump's order goes farther, though, wading into the controversial issue of how much coercion is justified in eliminating encampments. The Attorney General and the other federal agencies, it said, should take steps to ensure that grants go to states and cities that enforce prohibitions on open illicit drug use, urban camping and loitering and squatting. Homeless advocacy organizations saw those edicts as a push for criminalization of homelessness and mental illness. 'We'll be back to the days of 'One Flew Over the Cuckcoo's Nest,' 'Berg said, referring to the 1962 novel and subsequent movie dramatizing oppressive conditions in mental health institutions. Defending Housing First as a proven strategy that is the most cost-effective way to get people off the street, Berg said the order encourages agencies to use the money in less cost-effective ways. 'What we want to do is reduce homelessness,' he said. 'I'm not sure that is the goal of the Trump administration.' The National Homelessness Law Center said in a statement saying, 'This Executive Order is rooted in outdated, racist myths about homelessness and will undoubtedly make homelessness worse.... Trump's actions will force more people into homelessness, divert taxpayer money away from people in need, and make it harder for local communities to solve homelessness.' Murray, who describes himself as not a fan of Housing First, noted that key policies pressed in the order—civil commitment, encampment removal and substance use treatment—are already gaining prominence in the state and local response to homelessness. 'We all think if it came from Trump it is horrible,' Murray said. 'It is certainly overbearing. It certainly misses some nuances of what real people with mental illness and substance use are like. But we've started down the path of most of this stuff.' His main concern was that the order might be interpreted to apply to Section 8, the primary federal financial tool for getting homeless people into housing. What would happen, he asked, if someone with a voucher refused treatment? 'It might encourage more people to stay on the streets,' he said. 'Getting people into treatment isn't easy.'
NBC News
an hour ago
- NBC News
The next big health care fight that's splitting Republicans: From the Politics Desk
Welcome to the online version of From the Politics Desk, an evening newsletter that brings you the NBC News Politics team's latest reporting and analysis from the White House, Capitol Hill and the campaign trail. Happy Friday! In today's edition, Sahil Kapur notes that a looming Obamacare deadline is dividing Republicans on Capitol Hill. Plus, Kristen Welker breaks down the political fallout thus far from the Jeffrey Epstein saga. And Scott Bland answers this week's reader question on Texas Republicans' redistricting efforts. — Adam Wollner The next big health care fight that's splitting Republicans By Sahil Kapur After passing President Donald Trump's sweeping megabill that included steep cuts to Medicaid, Republicans have another big health care fight on their hands. GOP leaders are facing growing calls from their members to extend a bucket of funding for the Affordable Care Act that is set to expire at the end of this year as some look to avert insurance premium hikes and millions of Americans losing their health coverage. But the cause faces opposition from conservatives who detest Obamacare and don't want to lift a finger to protect it. Some argue it'd be too expensive to continue the premium tax credits, which cost over $30 billion per year and were initially adopted as part of a Covid-19 response. The nonpartisan Congressional Budget Office projects that about 5 million Americans will lose their insurance by 2034 if the money expires. The divide: Rep. Brian Fitzpatrick, R-Pa., who represents a swing district that Trump lost in 2024, said that Congress should continue those ACA tax credits in order to avoid price increases. 'I think we gotta be doing everything to keep costs low across the board — health care, groceries, energy, all of the above. So I am currently working on addressing that as we speak,' he said. But Rep. Andy Harris, R-Md., the chair of the hard-right House Freedom Caucus, said he 'absolutely' wants that funding to end. 'It'll cost hundreds of billions of dollars. Can't afford it,' he said. 'That was a Covid-era policy. Newsflash to America: Covid is over.' For now, top Republican leaders are keeping their powder dry about whether — or how — they will take up the issue. 'I think that goes to the end of the calendar year, so we'll have discussion about the issue later. But it hasn't come up yet,' House Speaker Mike Johnson, R-La., said when asked about an ACA subsidy extension. 'But it's on the radar.' A midterm warning: Veteran GOP pollsters Tony Fabrizio and Bob Ward recently released a memo warning that extending the health care tax credits is broadly popular, even with 'solid majorities of Trump voters and [s]wing voters.' They warned that the GOP will pay a 'political penalty' in the competitive districts in the 2026 midterm elections if the funding expires on schedule. Analysis by Kristen Welker The Jeffrey Epstein saga is the political headache that won't go away for President Donald Trump, as the drip-drip of new reporting on his past relationship with the convicted sex offender and repeated attempts to deflect have only fed the story. It's the first time we've really seen Trump's base break with him to this degree. Even though the impulse to rally around their leader remains as each new story breaks, no matter how Trump tries to change the subject, the calls for his administration to release more information from the Epstein files are only growing louder. The issue transcends politics — it's a devastating reminder of the victims of the crimes committed by Epstein and those who enabled him. As far as how it's playing out on Capitol Hill, Democrats and even some Republicans are trying to hold the Trump administration's feet to the fire. Both parties believe the GOP could pay a political price on the issue as they look to defend their congressional majorities in next year's midterms. That includes Rep. Thomas Massie, R-Ky., one of our guests on 'Meet the Press' this Sunday. 'People will become apathetic again. They'll say, we elected President Trump. We gave him a majority in the House and the Senate, and they couldn't even release evidence of an underage sex trafficking ring. They couldn't even bring themselves to release that. I thought we were the party of family values, and I guess we're not,' Massie said this week on the 'Redacted' podcast. And Democrats, including Rep. Ro Khanna of California — another one of our guests this Sunday — argue the issue has salience on multiple fronts. They note it divides Trump and his base while also making a relatively popular appeal for transparency, one piece of a broader Democratic line of attack that the administration isn't being open with the American people. While it's unsurprising that Democrats overwhelmingly disapprove of how the Trump administration is handling the Epstein files, according to a recent Quinnipiac University poll, 71% of independents disapprove, too. And Republicans are about evenly divided, with 40% approving and 36% disapproving of the administration's handling of the issue. The political cost for Republicans isn't clear yet. Will it depress the enthusiasm of voters Republicans are scrambling to motivate to turn out with Trump not on the ballot? Will it force the party onto the defense at a time where it needs to be cementing public sentiment about its landmark tax cuts and spending bill, which Democrats are already weaponizing as a key midterm issue? Could Democrats overplay their hand if it overshadows their message on the most important issue to many voters, the economy? We'll discuss this and more on this Sunday's 'Meet the Press.' In addition to Khanna and Massie, House Speaker Mike Johnson, R-La., and Sen. Lindsey Graham, R-S.C., will also be joining us. Thanks to everyone who emailed us! This week's reader question is on Republicans' attempts to draw new congressional maps in Texas. 'Is it legal what Gov. Greg Abbott and Texas Republicans want to do for Trump?' To answer that, we turned to senior politics editor Scott Bland. Here's his response: Redistricting happens every decade after the decennial census, so that each state has representation in the House of Representatives reflecting its official population and each district in a state has the same number of people in it. But this isn't the first time someone has moved to change the maps mid-decade. In fact, this isn't even the first time it's happened in Texas. In 2002, Texas Republicans gained full control of the state Legislature, and they decided the following year to draw a new map to replace a court-drawn one that had been imposed for that decade — and to increase the GOP advantage in the state. 'I'm the majority leader and we want more seats,' Rep. Tom DeLay, R-Texas, told reporters at the time. What flies in Texas doesn't necessarily fly everywhere, though. Colorado Republicans also tried to redraw maps in their state in 2003, but the state Supreme Court ruled that the state Constitution forbade revisiting the maps more than once per decade. While Democrats are eager to fight back against the GOP's effort to draw more red seats in Texas, such obstacles could stand in their way. As New York Democratic Party Chair Jay Jacobs told Politico this week, 'I understand those in New York who are watching what's happening in Texas and Ohio want to offset their unfair advantage.' But, he added, 'The [state] Constitution seems pretty clear that this redistricting process should be done every 10 years.'
